Seikagaku Corp
TSE:4548
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
607
805
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Seikagaku Corp
Net Income (Common)
Seikagaku Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Seikagaku Corp
TSE:4548
|
Net Income (Common)
-ÂĄ488m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Income (Common)
ÂĄ33.1B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Income (Common)
ÂĄ279.9B
|
CAGR 3-Years
65%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-2%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Income (Common)
ÂĄ449.1B
|
CAGR 3-Years
60%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Income (Common)
ÂĄ397.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
21%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Net Income (Common)
ÂĄ124.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
Seikagaku Corp
Glance View
Seikagaku Corp. manufactures pharmaceuticals and medical devices with glycoconjugates; specifically, glycosaminoglycans (GAG) such as hyaluronic acid; as well as enzymes that act on GAG. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 913 full-time employees. The company went IPO on 2004-03-23. The firm operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.
See Also
What is Seikagaku Corp's Net Income (Common)?
Net Income (Common)
-488m
JPY
Based on the financial report for Sep 30, 2025, Seikagaku Corp's Net Income (Common) amounts to -488m JPY.